medigraphic.com
ISSN 0210-5187 (Electronic)

2009, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2009; 37 (1)

Cutaneous pleomorphic malignant fibrous histiocytoma with a rapidly growing

AL Morales, P Zaballos, C Ros, MP Grasa, FJC Carapeto

Language: Spanish
References: 24
Page: 58-63
PDF size: 238.30 Kb.


ABSTRACT

Malignant fibrous histiocytoma,(MFH) is the most common soft-part sarcoma arising between the fourth an fifth decades of life, that usually involves the proximal lower extremities. Its histology has shown a wide variety of cell morphology, including storiform-pleomophic (fibroblastic or histiocytic cells dominant), myxoid, giant cell and inflammatory types. The most usual presentation is a tumoral lesion located within skeletal muscle that may spread to the skin as a painless nodule. We report a 82-years-old man who was seen with 7-month history of a rapidly growing and asynthomatic tumour of the left flank. Histologically the tumor showed a typical storiform pattern consisting of atypical histiocytic and fibroblastic cells. The cells were positive for vimentina, lisozima and CD68. These findings were compatible with a pleomorphic malignant fibrous histiocytoma. We review the clinical manifestations, histological findings and histogenesis of this tumour, and the different therapeutical options.


REFERENCES

  1. Andrew JE, Silver DN, Latter R. Sarcomas involving the skin and superficial tissues. En Friedman RJ, Rigel DS, Kopf AW, Harris MN, Baker D (eds. ). Cancer of the skin. Philadelphia: WB Saunders Company, 1991: 263-87.

  2. O’Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer 1964;17:1445-55.

  3. Stout AP, Lattes R. Tumors of the soft tissues. In Atlas of Tumor Pathology, series 2, fascicle 1. Washington DC. Armed Forces Institute of Pathology, 1967.

  4. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma. An analysis of 200 cases. Cancer 1978;41:2250-66.

  5. Enzinger FM, Weiss SW. Soft Tissue Tumors (ed 3). St Louis, Mosby, 1995.

  6. Martín E, Arnau A, Cantó A. Fibrohistiocitoma maligno de pared torácica. Recidiva temprana tras cirugía. Arch Bronconeumol 1998;34:467-8.

  7. Fletcher CDM, PaTh MRC. Pleomorphic malignant histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992;16:213-28.

  8. Grasa MP, Simal E, Lázaro J, Domínguez M , Gracia MT, Martín J, Carapeto FJ. Fibrohistiocitoma maligno. Variante mixoide. Actas Dermosifiliogr 1988;79:307-11.

  9. Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma. A retrospective study of 167 cases. Cancer 1980;45:167-78.

  10. Kauffman SL, Stout AO. Histiocytic tumors (fibrous xanthoma and histiocytoma) in children. Cancer 1961;14:469-82.

  11. Hamada T, Komiya S, Hiraoka K, Zenmyo M, Morimatsu M, Inoue A. Il-6 in a pleomorphic type of malignant fibrous histiocytoma presenting high fever. Hum Pathol 1998;29: 758-61.

  12. Merimsky O, Kollender Y, Issakov J, Bickels J, Flusser G, Gutman M et al. Multiple primary malignancies in association with soft tissue sarcomas. Cancer 2001;91:1363-71.

  13. Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE, Romsdahl MM. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer 1992;69:2098-103.

  14. Bertoni F, Capanna R, Biagini R et al. Malignant fibrous histiocytoma of soft tissue: An analysis of 78 cases located and deeply seated in the extremities. Cancer 1985;56:356-67.

  15. Rydholm A, Mandahl N, Heim S, Kreicberg A, Willein H, Mitelman F. Malignant Fibrous Histiocytoma with a 19 p + marker chromo some have increased relapse rate. Genes Chromosom Cancer 1990;2:296-9.

  16. Montgomery E, Fisher C. Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology 2001;38:499-509.

  17. Sánchez J, Fernández G, Porras J, Valks R, Fraga J, Aragües M. Placa inflamatoria como manifestación clínica de un fibrohistiocitoma maligno recurrente. Actas Dermosifiliogr 1996;87:186-90.

  18. Chibon F, Mairal A, Fréneaux P, Terrier P, Coindre JM, Sastre X, Aurias A. The RB1 gene is the target of chromosome 13 delections in malignant fibrous histiocytoma. Cancer Research 2000;60:6339-45.

  19. Binder SW, Said JW, Shintaku P, Pinkus GS. A histiocyte-specific marker in the diagnosis of malignant fibrous histiocytoma. Use of monoclonal Antibody KP-1 (CD 68). Am J Clin Pathol 1992;97:759-63.

  20. Erlandson R, Woodruff JM. Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Hum Pathol 1998;29:1372-81.

  21. Bell RS, O’Sullivan B, Liu FF, Powell J, Langer F, Fornasier VL et al. The surgical margin in soft-tissue sarcoma. J Bone Joint Surg Am 1989;71:370-5.

  22. Zagars GK, Mullen JR, Pollack A. Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1996;34:983-94.

  23. Benjamin RS, Terjanian TO, Fenoglio CJ et al. The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft-tissue sarcomas of the extremities. In: Salmon SE, ed. Adjuvant therapy of cancer, vol. 5. Orlando: Grune and Stratton, 1987;734-44.

  24. Wilson RE, Wood RC, Lerner HL et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma: Combined results of two randomised trials. Arch Surg 1986;121: 1354-9.




2020     |     www.medigraphic.com